Treatment guidelines for Guillain-Barré Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were published in 2023 and 2021, respectively. Developed by a team of experts, these guidelines offer evidence-based recommendations grounded in the latest medical research and are published in peer-reviewed medical journals.

Dr. Mamatha Pasnoor, Professor of Neurology at the University of Kansas Medical Center and member of the Global Medical Advisory Board, specializes in treating patients with GBS, CIDP, and Multifocal Motor Neuropathy (MMN). She also supports patients in accessing clinical trials. In this webinar, Dr. Pasnoor will discuss the GBS and CIDP diagnosis and treatment guidelines that inform clinical decision-making. We’ll explore how the guidelines were developed, how healthcare providers use them, and highlight key treatment recommendations.

While MMN-specific guidelines have not been recently updated and will not be a primary focus of the discussion, MMN patients and their families may still find value in learning how treatment guidelines are created and applied across related conditions.

Who should participate?

GBS and CIDP patients and their families will benefit most from this discussion, though healthcare professionals may also find the topic informative. MMN patients may be interested as well, particularly in understanding the broader process behind treatment guideline development and implementation.